Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546157 | 0.78 | GPR174 (0.37) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31546208 | 0.76 | GLA (0.34) | LMNAKMT2APOLB | |
| SCHEMBL31546173 | 0.76 | NPC1 (0.31) | KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31546048 | 0.73 | NPC1 (0.40) | MAPTLMNAKMT2ANPC1RAB9A | |
| SCHEMBL6132937 | 0.71 | MEN1 (0.54) | MAPTLMNAABL1KMT2ARIN1 | |
| SCHEMBL31546140 | 0.70 | KMT2A (0.33) | KMT2A | |
| SCHEMBL4763549 | 0.69 | CA1 (0.39) | KMT2AALDH1A1MAPK1 | |
| SCHEMBL31546073 | 0.67 | SLC6A4 (0.46) | — | |
| SCHEMBL3691727 | 0.66 | RAB9A (0.33) | NPC1RAB9A | |
| SCHEMBL31546100 | 0.65 | ALOX5 (0.57) | KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | Structure Holdings, LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | Structure Holdings, LLC (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090440-A1 | NOVEL CYCLIC ACETAL COMPOUNDS WITH ALDEHYDE OR KETONE FUNCTIONALITIES AND USES THEREOF | OR51E2, TAS2R5, TRPA1 | MAPT 4470/4885LMNA 4652/4885ABL1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.